Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
7 hedge funds and large institutions have $328K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
17% more capital invested
Capital invested by funds: $280K → $328K (+$48K)
17% more funds holding
Funds holding: 6 → 7 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.15K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $117K | – | – | – |
|
|
PA
2
Perceptive Advisors
New York
| $108K | – | – | – |
|
|
MWNA
3
Marshall Wace North America
New York
| $33K | – | – | – |
|
|
SFM
4
Sphera Funds Management
Tel Aviv,
Israel
| $33K | – | – | – |
|
|
PC
5
PointState Capital
New York
| $26K | – | – | – |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $6K | +$3.15K | +20,070 | New |
|
|
CIA
7
Compass Ion Advisors
Conshohocken,
Pennsylvania
| $5K | – | – | – |
|
OTLKW Hedge Fund Activity: Q2 2020 in Review
7 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q2 2020, worth a combined $328K — up 17% from $280K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new OTLKW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $3.15K.
- 7 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q2 2020, up from 6 in Q1 2020.
- Funds reported $328K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q2 2020, up 17% quarter-over-quarter.
- 1 fund opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q2 2020 and 0 closed out, a net change of +1 holder.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 buyer in Q2 2020 was Susquehanna International Group, an estimated $3.15K added.
Based on aggregated 13F filings for Q2 2020.